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Aretaeus of Cappadocia (1st century CE) described 
a young man with chronic and recurring abdominal 
distress possibly representing the first recorded instance 
of Crohn disease (CD).1-3 More evidence that this disease 
was extant for many years comes from the description 
of the 10th century English king, Alfred “the great,” 
who suffered for many years from what was a typical 
enteritis but also had anal fistula and/or abscess.4 In 
medieval times, Antonio Benivieni (1443-1502) 
described the multi-ulcerated small intestine in a 
patient dying after a prolonged dysentery-like course. 
Louis XIII, King of France (1601-1643) died at the age 
of 42 after decades of abdominal pain, fever, bloody 
diarrhea and rectal/perianal abscesses.4 However, it was 
in 1761 that Giovanni Battista Morgagni (1682-1771), 
a towering figure in the history of medicine, described 
a 20-year-old man with typical regional ileitis, who 
died. Morgagni autopsied him and described typical 
CD lesions of both the small and large intestine, 
including erosions, ulcerations and perforations with 
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lymphadenopathy. In the following 150 years, cases 
likely to be Crohn disease were reported by Mathew 
Baillie, Colles, Cruveilhier, Fenwick, Fröhlich and many 
others. Notable was the description of “singular case 
of stricture and thickening of the ileum” by Coombe 
and Saunders in 1813 and “inflammatory fibrous 
colon tumour” by Rudolph Virchow.5,6 None of these, 
however, described completely the unique pathological 
and clinical entity that is Crohn disease, although the 
Scottish surgeon Thomas Kennedy Dalziel (1861-1924), 
in his report of “chronic interstitial enteritis,” came 
close.
It remained to the group of clinician-investigators 
at The Mount Sinai Hospital, New York, Burrill B. 
Crohn, Gordon Oppenheimer and Leon Ginzburg, to 
publish the classic paper, entitled “Regional ileitis: a 
pathological and clinical entity” in 19327-9, identifying 
14 patients with symptoms and surgical intestinal 
abnormalities, which they recognized as a singular 
entity.
Crohn disease, as this entity was later coined, is 
a chronic inflammatory disease of unknown etiology, 
which potentially involves the gastrointestinal tract 
from the mouth to the perianal area.
CD may affect people in early childhood until 
late adulthood, but younger individuals, including 
teenagers and young adults, are more often affected. 
Afflicted patients have a significant decrease in the 
quality of life because of the marked morbidity. 
This disease also has a significant economic impact 
since most patients are affected in their productive 
years. The incidence seems to be increasing worldwide, 
even in low-incidence regions, probably because 
of better diagnosis. Environmental factors as well 
as changes in life style may also have an impact. 
The highest incidence rate has been reported in Canada 
(248/100,000 inhabitants), while in Asia the rate is less 
than 6.3/100,000 inhabitants.
Although the etiology is still not understood, 
several theories have been proposed over the years.
Mycobacterium avium subspecies paratuberculosis 
has been implicated in the pathogenesis of CD, 
reinforced by the great similarity between CD and 
cattle’s Johne disease. This association has been 
supported by many studies10 but has not been proven by 
either identification of mycobacteria in tissue samples 
or by consistent culture of an organism. Another theory 
suggests there is an inherited abnormal response to the 
high burden of bacteria in the gastrointestinal lumen, 
resulting in an exaggerated inflammatory response.11 
A third theory claims that these genetic defects are 
responsible for a diminished inflammatory response 
and therefore accumulation of stimuli in the intestinal 
lumen which activate the adaptive immune system.12
Clinical manifestations vary greatly in the manner 
gastrointestinal and extra-intestinal involvement is 
expressed. The majority of patients have small bowel 
involvement, predominantly in the ileum, while as 
many as 20% have the disease confined to the colon. 
Quite frequently, symptoms are present two to three 
years before the diagnosis is established. Patients 
typically have diarrhea, often bloody, abdominal pain, 
fatigue, weight loss with emaciation, and fever.13 
Transmural inflammation is characteristic often 
leading to sinus tract(s) formation which, because 
of the characteristic serositis, leads to bowel-to-
bowel adhesions and subsequent fistulas. The image 
above shows many of the characteristic features of 
Crohn disease with adherent loops of thick-walled 
(“transmural inflammation”) bowel showing acute and 
chronic serositis and fistula formation as evidenced by 
the metal probes.14 Perianal involvement is often seen 
with pain, fissures, perianal abscesses, and fistulas. 
Other gastrointestinal manifestations include oral 
aphthous ulcers, odynophagia or dysphagia, gastric 
outlet obstruction15 and gallstones.16
Extraintestinal manifestations that can be seen 
are arthritis, skin and eye involvement, primary 
sclerosing cholangitis leading to secondary biliary 
cirrhosis, secondary amyloidosis, hypercoagulability, 
renal stones, osteoporosis, vitamin B12 deficiency and 
pulmonary involvement.17-22
Currently, diagnosis of CD usually requires imaging 
studies, endoscopy, serologic markers and evaluation 
of inflammatory-marker protein tests.
Colonoscopy with terminal ileum examination 
is used to establish the diagnosis of ileocolonic CD. 
Focal ulcerations intermingled with normal-appearing 
(“skip”) areas is typical. Polypoid mucosal changes give 
a distinctive cobblestone appearance, characteristic of 
CD, although, in the large intestine, longitudal ulcers, 
resembling furrows made by a garden rake, are often 
seen. Carcinoma can develop after many years of 
active disease, but is exceedingly rare with modern 
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methods of following patients as well as with effective 
therapies.23 Wireless capsule endoscopy is an option 
to study the proximal segments of the intestine, when 
ileocolonoscopy fails to disclose a diagnostic lesion.24 
The upper gastrointestinal tract may also be studied 
by small bowel follow-through series, which allows 
for the documentation of the length and location 
of any strictures. Serologic markers are often helpful 
in distinguishing CD from ulcerative colitis, as well 
as in monitoring the disease course. In this setting, 
antineutrophil cytoplasmic antibody (pANCA) and 
anti-Saccharomyces cerevisiae antibody (ASCA) have 
a sensitivity of 40% - 60% with greater than 90% 
specificity in distinguishing patients with inflammatory 
bowel disease from controls.25
Keywords: Crohn Disease, Pathology, History of 
Medicine.
REFERENCES
1. Banerjee AK, Peters TJ. The history of Crohn’s disease. J R 
Coll Physicians Lond. 1989;23(2):121-4. PMid:2659781.
2. Mulder DJ, Noble AJ, Justinich CJ, Duffin JM. A tale 
of two diseases: the history of inflammatory bowel 
disease. J Crohn’s Colitis. 2014;8(5):341-8. http://dx.doi.
org/10.1016/j.crohns.2013.09.009. PMid:24094598.
3. Kirsner JB. The historical basis of the idiopathic 
inflammatory bowel diseases. Inflamm Bowel Dis. 
1965;1:2-26.
4. Horspool D. King Alfred: burnt cakes and other legends. 
London: Profile Books; 2006. p.154.
5. Bernier JJ, Chevallier P, Teysseire D, André J. La maladie 
de Louis XII. Tuberculose intestinale ou maladie de 
Crohn? Nouv Presse Med. 1981;10(27):2243, 2247-50. 
PMid:7022367.
6. Aufses AH Jr. The history of Crohn’s disease. Surg 
Clin North Am. 2001;81(1):1-11, vii. http://dx.doi.
org/10.1016/S0039-6109(05)70270-X. PMid:11218157.
7. Crohn BB, Ginzburg L, Oppenheimer GD. Regional 
ileitis: a pathological and clinical entity. JAMA. 
1932;99(16):1323-9. http://dx.doi.org/10.1001/
jama.1932.02740680019005.
8. Campos FGMC, Kotze PG. Burrill Bernard Crohn (1884-
1983): the man behind the disease. Arq Bras Cir Dig. 
2013;26(4):253-5. http://dx.doi.org/10.1590/S0102-
67202013000400001. PMid:24510030.
9. Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks 
RK. Clinical features and natural history of Crohn’s 
disease. Gastroenterology. 1979;77(4 Pt 2):898-906. 
PMid:381094.
10. Naser SA, Sagramsingh SR, Naser AS, Thanigachalam S. 
Mycobacterium avium subspecies paratuberculosis causes 
Crohn’s disease in some inflammatory bowel disease 
patients. World J Gastroenterol. 2014;20(23):7403-
15. http://dx.doi.org/10.3748/wjg.v20.i23.7403. 
PMid:24966610.
11. Marks DJB, Segal AW. Innate immunity in inflammatory 
bowel disease: a disease hypothesis. J Pathol. 
2008;214(2):260-6. http://dx.doi.org/10.1002/
path.2291. PMid:18161747.
12. Comalada M, Peppelenbosch MP. Impaired innate immunity 
in Crohn’s disease. Trends Mol Med. 2006;12(9):397-9. 
http://dx.doi.org/10.1016/j.molmed.2006.07.005. 
PMid:16890491.
13. Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks 
RK. Clinical features and natural history of Crohn’s 
disease. Gastroenterology. 1979;77(4 Pt 2):898-906. 
PMid:381094.
14. Geller SA. Pathology of inflammatory bowel diseases. 
In: Targan S, Shanahan F, editors. Inflammatory bowel 
disease. Baltimore: Williams and Wilkins; 1994. chap. 
23; p. 336-351.
15. Annunziata ML, Caviglia R, Papparella LG, Cicala M. 
Upper gastrointestinal involvement of Crohn’s disease: 
a prospective study on the role of upper endoscopy in 
the diagnostic work-up. Dig Dis Sci. 2012;57(6):1618-
23. http://dx.doi.org/10.1007/s10620-012-2072-0. 
PMid:22350786.
16. Hutchinson R, Tyrrell PN, Kumar D, Dunn JA, Li JK, Allan 
RN. Pathogenesis of gall stones in Crohn’s disease: an 
alternative explanation. Gut. 1994;35(1):94-7. http://
dx.doi.org/10.1136/gut.35.1.94. PMid:8307459.
17. Gravallese EM, Kantrowitz FG. Arthritic manifestations 
of inflammatory bowel disease. Am J Gastroenterol. 
1988;83(7):703-9. PMid:3289378.
18. Huang BL, Chandra S, Shih DQ. Skin manifestations of 
inflammatory bowel disease. Front Physiol. 2012;3:13. 
http: / /dx.doi .org/10.3389/fphys.2012.00013. 
PMid:22347192.
19. Felekis T, Katsanos K, Kitsanou M, et al. Spectrum and 
frequency of ophthalmologic manifestations in patients 
with inflammatory bowel disease: a prospective single-
center study. Inflamm Bowel Dis. 2009;15(1):29-34. 
http://dx.doi.org/10.1002/ibd.20584. PMid:18626979.
20. Headstrom PD, Rulyak SJ, Lee SD. Prevalence of and 
risk factors for vitamin B(12) deficiency in patients with 
Crohn’s disease. Inflamm Bowel Dis. 2008;14(2):217-23. 
http://dx.doi.org/10.1002/ibd.20282. PMid:17886286.
21. Lu DG, Ji XQ, Liu X, Li HJ, Zhang CQ. Pulmonary 
manifestations of Crohn’s disease. World J Gastroenterol. 
2014;20(1):133-41. http://dx.doi.org/10.3748/wjg.v20.
i1.133. PMid:24415866.
Autopsy and Case Reports 2015; 5(2):5-8
Crohn disease
8
22. Marineaţă A, Rezuş E, Mihai C, Prelipcean CC. 
Extra intestinal manifestations and complications in 
inflammatory bowel disease. Rev Med Chir Soc Med Nat 
Iasi. 2014;118(2):279-88. PMid:25076688.
23. Greenstein AJ, Sachar D, Pucillo A, et al. Cancer in 
Crohn’s disease after diversionary surgery. A report of 
seven carcinomas occurring in excluded bowel. Am J Surg. 
1978;135(1):86-90. http://dx.doi.org/10.1016/0002-
9610(78)90015-6. PMid:623378.
24. Levesque BG, Cipriano LE, Chang SL, Lee KK, Owens DK, 
Garber AM. Cost effectiveness of alternative imaging 
strategies for the diagnosis of small-bowel Crohn’s 
disease. Clin Gastroenterol Hepatol. 2010;8(3):261-7, 
267.e1-4. http://dx.doi.org/10.1016/j.cgh.2009.10.032. 
PMid:19896559.
25. Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of 
serological markers in inflammatory bowel diseases: gadget 
or magic? World J Gastroenterol. 2007;13(14):2028-36. 
PMid:17465443.
Correspondence 
Stephen A. Geller 
Department of Pathology and Laboratory Medicine 
David Geffen School of Medicine, UCLA 
Los Angeles/CA – USA 
E-mail: geller16st@gmail.com
Fernando P. F. de Campos 
Divisão de Clínica Médica 
Hospital Universitário 
University of São Paulo 
São Paulo/SP – Brazil 
E-mail: fpfcampos@gmail.com
